The partnership with Bio-Rad Laboratories for global commercialization of GraftAssure™ is strategically important, leveraging Bio-Rad's established distribution network. However, investors should note that Oncocyte is still in the early stages of commercialization. The company's focus on both transplant and oncology verticals diversifies its portfolio but may also strain resources. Financial performance and market penetration rates in the coming quarters will be important indicators of the company's growth trajectory and long-term viability.